Avai Bio, Inc., formerly Avant Technologies, Inc., is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing cell-based therapies. The Company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an a-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments. It has secured Joint Venture and Licensing Agreements to develop both cell lines. Its diabetes program is focused on developing an insulin-producing cell line, then encapsulating those cells inside using SGAustria's Cell-in-a-Box technology to create a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes. The Company is partnering with biotech firms, universities, scientists, and clinicians to uncover solutions for diverse healthcare challenges.